



Singapore eDevelopment Limited

(Company Registration Number 200916763W)
7 Temasek Boulevard, #29-01B
Suntec Tower One, Singapore 038987

Impact Biomedical Achieves COVID-19 Success with Equivir and 3F Biofragrance

Singapore Exchange-listed Singapore eDevelopment Limited's ("**SeD**") (Stock Code 40V) wholly owned subsidiary Impact Biomedical Inc. ("**Impact Biomedical**") announced today that they proved *in vitro* success of Equivir and 3F Biofragrance against COVID-19 in independent laboratory testing. Impact Biomedical and Global Research and Discovery Group Sciences ("**GRDG**") contracted an independent university laboratory to challenge the compounds against the SARS-CoV-2 virus in their advanced Biosafety Level 3 containment facilities. Equivir is successful as a treatment as well as a prophylactic to protect cells against infection of the virus. Currently no known COVID-19 prophylactics have been developed. 3F Biofragrance is successful as a surface disinfectant by killing the virus in concentrations as low as 1/5000 after 15 seconds.

These *in vitro* results confirm the predictions of advanced computational molecular docking which showed that Equivir and Linebacker had binding with high affinity to the COVID-19 helicase and protease. Equivir and Linebacker also cause transformational changes to the ACE-2 receptor which interferes with the ability of the virus to interact with the receptor and infect the host cell. Binding affinity for components of 3F Biofragrance was also observed in molecular docking.

Equivir is patented and designed as a prophylactic to be deployed in a manner similar to a vitamin. It works by impeding virulence while also blocking multiple methods used by viruses to infect and replicate in host cells. Equivir treats and protects against diseases caused by not only SARS-CoV-2 but also other dangerous pathogens. Equivir has broad antiviral efficacy against multiple types of Influenza, Rhinovirus, Cholera, Ebola, and COVID-19.

Linebacker was created to shadow the Panacea Project, a US Defense Advanced Research Projects Agency (DARPA) program to provide novel, multi-target therapeutics for unmet physiological needs. Linebacker is under continuing research against COVID-19 as it showed efficacy against SARS and MERS in previous laboratory testing. Linebacker is a patented universal therapeutic medication with demonstrated effectiveness in neurological diseases including Parkinson's, many types of cancer, and multiple pathogens such as MRSA, E. coli, Cholera, A. baumannii, Influenza, SARS, MERS, Malaria, and Ebola.

3F Biofragrance was designed for the Open Air Defense Initiative, a strategy to protect large numbers of people where they gather such as containment areas, ports of entry, train stations, airports, convention centers, offices, schools, and hospitals. 3F Biofragrance technology also provides protection against mosquito-borne diseases such as Zika, Malaria and Dengue fever and is 10-fold more effective than DEET. 3F Antiviral Biofragrance is effective against E. coli, MRSA, Influenza, Rhinovirus, Tuberculosis, and COVID-19.

3F Biofragrance was developed in collaboration with Chemia Corporation ("**Chemia**"), world-renowned for the development of fragrances and flavors for personal, household, and industrial applications. The combination of GRDG's advanced scientific research and Chemia's expert formulation and global scale production infrastructure makes this patent pending technology powerful and effective at protecting people

from deadly pathogens and insects. “Chemia is proud to partner with GRDG to pioneer functional fragrances to not only enrich peoples’ lives, but save them as well,” said Thomas A. Meyer, Vice-President of Innovation and Sustainability at Chemia.

GRDG’s Chief Scientific Advisor is Dr. Roscoe M. Moore, Jr., the former United States Assistant Surgeon General and former Epidemic Intelligence Service Officer at Centers for Disease Control and Prevention or CDC. Dr. Moore said, “GRDG’s novel strategy of attacking diseases in multiple different ways is the future of effective pandemic response.”

GRDG’s Chief Strategy Advisor is Lieutenant Colonel William H. Lyerly Jr., retired Career Senior Executive / Scientific Professional from the U.S. Department of Homeland Security and retired U.S. Army Medical Service Corps Officer. Lieutenant Colonel Lyerly also served as a senior official in the U.S. Department of Health and Human Services, the U.S. Agency for International Development, and the U.S. Executive Office of the President (White House). Lieutenant Colonel Lyerly said, “The validation of these solutions demonstrates GRDG’s skill in providing comprehensive solutions to global health threats.”

Daryl Thompson, Director of Scientific Initiatives and founder of GRDG said, “I am happy to see that the 3F and Equivir biological countermeasures are performing as expected in independent efficacy testing. These positive results against the SARS-COV-2 virus now allow us to expeditiously move Equivir to clinical trials which we expect to be completed within the year. The 3F technology is ready for deployment in consumer products now.”

Impact Biomedical’s technology solutions have been developed in strategic partnership with GRDG. Mr. Chan Heng Fai. “I am greatly encouraged with the results and the team’s contribution to this cause. We hope this will eventually prove to be beneficial to everyone and we look forward to more exciting discoveries.” said Mr. Chan.

GRDG is in active engagement with large global corporations to position the technologies for rapid integration into multiple distribution routes to deploy these life-saving solutions worldwide.

Our intention in relation to the Covid-19 situation is to establish strong novel research data which will then be further developed and licensed to a major pharmaceutical company for integration and eventual deployment as treatments for diseases.

Shareholders and potential investors of SeD are advised to read this Press Release and any further announcements made by SeD carefully. Shareholders and potential investors of SeD are advised to refrain from taking any action with respect to their securities in SeD which may be prejudicial to their interests, and to exercise caution when dealing in the securities of SeD. Shareholders and potential investors of SeD should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take

End of Press Release

About Singapore eDevelopment Limited

Incorporated on 9 September 2009 and listed on the Singapore Exchange in July 2010, Singapore eDevelopment Limited is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities.

For more information, please visit: www.SeD.com.sg or email contact@sed.com.sg.

About Impact BioMedical, Inc.

Impact BioMedical, Inc. ("**Impact BioMedical**") is a wholly-owned direct subsidiary of Global BioMedical Pte. Ltd., which in turn is a wholly-owned direct subsidiary of Singapore eDevelopment Limited, a company listed on the Singapore Exchange.

Impact BioMedical strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into the scientific expertise of GRDG Sciences, LLC. and Australian Exchange-listed Holista CollTech Limited, Impact BioMedical pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition, and treatment of neurological, oncological and immuno related diseases.

About GRDG Sciences, LLC.

GRDG Sciences, LLC is an advanced research team formed in Florida by natural products discovery drug research scientist, Daryl Thompson.

For more information, please visit: <http://www.globalrdg.com>.

This Press Release has been reviewed by the Company's Sponsor, Hong Leong Finance Limited. It has not been examined or approved by the Exchange and the Exchange assumes no responsibility for the contents of this Press Release, including the correctness of any of the statements or opinions made or reports contained in this Press Release.

The contact person for the Sponsor is Mr Tang Yeng Yuen, Vice President, Head of Corporate Finance, Hong Leong Finance Limited, at 16 Raffles Quay, #01-05 Hong Leong Building, Singapore 048581, telephone (+65) 6415 9886.